NCT06633315View on ClinicalTrials.gov

Esketamine Combined With Dexmedetomidine Sedation in Head MRI Examination of Children With Autism Spectrum Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
Autism Spectrum DisorderDexmedetomidineEsketamineSedation
Interventions
OTHER

low dos dexmedetomidine

received dexmedetomidine 2.5 μ g/kg nasal drops

OTHER

high dos dexmedetomidine

received dexmedetomidine 3 μ g/kg nasal drops

OTHER

dexmedetomidine and esketamine

received dexmedetomidine 2 μ g/kg nasal drops plus ketamine 0.5 mg/kg nasal drops

Trial Locations (1)

43000

Maternal and Child Health Hospital of Hubei Province,, Wuhan

All Listed Sponsors
lead

Maternal and Child Health Hospital of Hubei Province

OTHER